104.31 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||98.00 x 1000|
|Ask||115.00 x 900|
|Day's Range||99.21 - 104.97|
|52 Week Range||98.18 - 130.00|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||7.79|
|Earnings Date||Apr 30, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||125.55|
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 17, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) was named as a defendant, along with Smiths Medical ASD, Inc., in a lawsuit filed in federal court by Sandoz Inc. and RareGen, LLC on April 16, 2019. The lawsuit alleges that United Therapeutics engaged in anticompetitive conduct in connection with plaintiffs' efforts to launch their generic version of Remodulin® (treprostinil) Injection. United Therapeutics was founded with the goal of serving patients with pulmonary arterial hypertension (PAH), and that remains our focus today.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as United Therapeutics Corporation (NASDAQ:UTHR), with a market capitalization of US$4.8b, rarely draw their attention from the investing commun...
United Therapeutics Corp NASDAQ/NGS:UTHRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for UTHR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding UTHR are favorable with net inflows of $70.50 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 8, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event. Accordingly, United Therapeutics has decided to discontinue further esuberaprost development.
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) reported Thursday mixed results from a phase 3 clinical trial for its attention deficit hyperactivity disorder treatment — and investors were not pleased. The Rockville company, which focuses on products for central nervous system diseases, failed to demonstrate that a 600-milligram dose of its drug candidate, called viloxazine hydrochloride, could effectively reduce ADHD symptoms in adolescents. The stock dipped Thursday as much as 4 percent to $32.90 per share before crawling up to $34.18, a 0.58 percent drop from Wednesday's closing price, by 3 p.m. But Supernus President and CEO Jack Khattar said this latest outcome won't stop the company from advancing the product to market, according to remarks he made on a conference call about the results.
How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 2.45% for United Therapeutics (UTHR) based on the stock’s closing
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 12, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Oppenheimer 29th Annual Healthcare Conference in New York City. The presentation will take place on Tuesday, March 19, 2019, at 1:35 PM Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.
United Therapeutics Corporation (NASDAQ:UTHR) shareholders might be concerned after seeing the share price drop 13% in the last week. But the silver lining is the stock is up over fiveRead More...
The results for Q4 and the full year 2018 from MannKind Corp. (MNKD) were a pleasant surprise. MNKD also received a milestone payment of $10 million, which reflects $6.4M under the United Therapeutics (UTHR) license agreement, $3.8M from the UT research agreement and $0.1M from the Cipla marketing and distribution agreement. On the earnings call, management shared results related to Afrezza’s quarterly prescription growth since 2017.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 4, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on Monday, March 11, 2019, at 4:10 PM Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.
Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 27, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ...